

03-18-2004

Form PTO-1595
(Rev. 10/02)
OMB No. 0651-0027 (exp. 6/30/2005)



U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

102698151

To the Honorable Commissioner of Patent and Trademarks: Please record the attached documents or copy thereof.

1. Name of conveying party(ies): 3.15.04
metaGen Pharmaceuticals GmbH i.L.

2. Name and address of receiving party(ies):

Name: André Rosenthal

Internal Address: _____

Street Address: Koppenplatz 10

City: Berlin Country: Germany Zip: D-10115

Additional names(s) or address(es) attached ☒ Yes ☐ No

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of Conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other

Execution Date: March 3, 2004

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

B. Patent No.(s)

6,620,923

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Millen White Zelano & Branigan, P.C.

Internal Address: Suite 1400

Street Address: 2200 Clarendon Boulevard

City: Arlington State: VA Zip: 22201

6. Total number of applications and patents involved: **1**

7. Total fee (37 CFR 3.41).....\$ **40.00**

- ☒ Enclosed
☐ Authorized to be charged to deposit account

8. Deposit Account number:

13-3402

DO NOT USE THIS SPACE

9. Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

John A. Sopp, Reg. No. 33,103

Name of Person Signing

Signature

March 15, 2004

Date

03/17/2004 METACHE 00000159 6620923

01 FC:8021

40.00 DP

Total number of pages including cover sheet, attachments, and documents:

21

JAS/stm/K:VALBRE12/PTO-1595.doc

PATENT
REEL: 015083 FRAME: 0336

RECORDATION FORM COVER SHEET
PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Honorable Commissioner of Patent and Trademarks: Please record the attached documents or copy thereof.

2. Name and address of receiving party(ies):

Name: **Bernd HINZMANN**

Street Address: **Parkstrasse 19**

City: **Berlin** Country: **Germany** Zip: **D-13127**

3. Name and address of receiving party(ies):

Name: **Thomas SPECHT**

Street Address: **Grabenstrasse 14**

City: **Berlin** Country: **Germany** Zip: **D-12209**

4. Name and address of receiving party(ies):

Name: **Christian PILARSKY**

Street Address: **Heinrich-Lange-Strasse 13c**

City: **Berlin** Country: **Germany** Zip: **D-01474**



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 BerlinEinwurf-Einschreiben/registered mailProf. André Rosenthal
Waldmüllerstr. 6

14 482 Potsdam

Dr. Lyn Leaper, Astex
VP, Intellectual Propertyphone: ++44(0)1223 226 200
fax: ++44(0)1223 226 201Dr. Uta Schwidetzky
Patents Managerphone: ++49(0)30 45082 265
fax: ++49(0)30 45082 101Berlin, February 23rd, 2004**Re: assignment of metagen patent applications**Sehr geehrter Prof. Rosenthal,
Dear Prof. Rosenthal,Wir, metaGen Pharmaceuticals GmbH, Oudenarder Strasse 16, D-13347 Berlin,
übertragen hiermit die Patentanmeldung(en)

1. DE102 25 180.0 (MET/DE/0206), PCT/DE/ 03/01824 (MET/EP/0315), "Protein or peptide and coding nucleic acid and use thereof"
2. DE103 45 011.4 (MET/DE/0331), „Use of metaRING binding substances for diagnosing and treatment of cancer"
3. DE 103 45 010.6 (MET/DE/0333) „Use of NIFIE14 agonists and/or antagonists for diagnosing and treatment of cancer"
4. DE 103 49 505.3 (MET/DE/0327), „Verwendung von Nukleinsäuren und Peptiden bzw. Proteinen zur Diagnose und Behandlung von Kolonkarzinomen"
5. DE102 34 901.0 (MET/DE/0202), PCT/DE03/02159 (MET/PCT/0324), „Use of MRP4 binding compounds for detecting and treating cancer"
6. DE 103 15 834.0 (MET/DE/0306), "Human nucleic acid sequences expressed in pancreatic carcinomas"
7. DE 103 22 134.4 (MET/DE/0321) "Human nucleic acid sequences expressed in prostate carcinomas" (appn II)
8. DE102 23 246.6 (MET/DE/0113), EP 03090148.2 (MET/EP/0319), US 10/442,658 (MET/US/0320), "Slit1 and MEGF4 isoforms and use thereof"
9. DE103 09 985.9 (MET/DE/0302) "Human nucleic acid sequences expressed in prostate carcinomas" (appn I)
10. DE198 18 620 A1 (MET/DE/9813), EP1071776 (MET/EP/0035), US divisional MET/US/0325 of US09/673,840 (MET/US/0036), JP2002531052T (MET/JP/0034), "New polypeptides and their nucleic acids, useful for treatment of bladder tumour and identification of therapeutic agents"

Handelsregister
AG Berlin-Charlottenburg
HRB 61730Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00Ust.Nr.
DE 185525651

www.metaGen.de



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin

11. DE198 18 619.3 (MET/DE/9814), EP1073742 (MET/EP/0038), US divisional MET/US/0323 of US09/673,841 (MET/US/0039), JP2002512023T (MET/JP/0037), "New nucleic acid sequences expressed in bladder tumour tissue, and derived polypeptides, for treatment of bladder tumour and identification of therapeutic agents"
12. DE198 13 835.0 (MET/DE/9805), EP1070125 (MET/EP/0011), US09/646,569 (MET/US/0012), JP2002506639T (MET/JP/0010): "Human nucleic acid sequences and protein products from normal breast tissue, useful for breast cancer therapy"
13. DE 198 13 839.3 (MET/DE/9804), EP 106 43 79 (MET/EP/0008), divisional EP 02090142.7 (MET/EP/0212), US 09/646,673 (MET/US/0009), divisional US 10/131,410 (MET/US/0214), JP2002506643T (MET/JP/0007): "Human nucleic acid sequences and protein products from tumour breast tissue, useful for breast cancer therapy"
- ➔ 14. DE198 17 948 A1 (MET/DE/9812), EP1071775 (MET/EP/0032), granted US patent 6,620,923 B1; US divisional US10/407,825 (MET/US/0310), JP2002532055T (MET/JP0031), "New nucleic acid sequences expressed in uterine cancer tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents"
15. DE198 17 946 A1 (MET/DE/9810), EP1071777 (MET/EP/0026), US09/647,788 (MET/US/0027), US divisional US10/387,348 (MET/US/0230), JP2002512017T (MET/JP/0025), "New nucleic acid sequences expressed in normal uterine tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents"
16. DE198 17 947.2 (MET/DE/9811), EP1080188 (MET/EP/0029), US09/673,400 (MET/US/0030), JP2002512024T (MET/JP/0028), "New nucleic acid sequences expressed in uterine myoma, and derived polypeptides, for treatment of uterine carcinoma and identification of therapeutic agents"
17. DE 198 16 395 A1 (MET/DE/9806), EP1068231 (MET/EP/0014), divisional from US09/646,777 (MET/US/0318), JP2002510486T (MET/JP/0013): "Human nucleic acid sequences from ovarian normal tissue"
18. DE198 17 557 A1 (MET/DE/9807), EP999 45687.4 (MET/EP/0017), divisional EP020 90198.9 (MET/EP/0215); US09/646,778 (MET/US/0018), divisional US10/272,138 (MET/US/0216), JP2002511252T (MET/JP/0016), "Human nucleic acid sequences from ovarian tumour tissue"
19. DE198 18 598 A1 (MET/DE/9808), EP1082420 (MET/EP/0020), divisional US10/330,551 (MET/US/0313), JP2002512022T (MET/JP/0019), "New nucleic acid sequences expressed in normal pancreatic tissues, and derived polypeptides, for treatment of pancreatic cancer and identification of therapeutic agents"
20. DE198 20 190 A1 (MET/DE/9809), EP1076700 (MET/EP/0023), US09/674,266 (MET/US/0024), JP2002512795T (MET/JP/0022), "Human nucleic acid sequences from pancreas tumour tissue"

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin

21. DE 198 11 194.0 (MET/DE/9803), EP1068318 (MET/EP/0005), divisional from US10/391,484 (MET/US/0229), JP2002505878T (MET/JP/0004): „New nucleic acid expressed at high level in normal prostatic tissue and encoded polypeptides, used to treat cancer and screen for therapeutic agents”
22. DE 198 11 193.2 (MET/DE/9802), EP 999177 85.0 (MET/EP/0002), divisional EP 02090141.9 (MET/EP/0211), US09/623,791 (MET/US/0003), divisional from US 09/623,791 (MET/US/0213), JP2002505877T (MET/JP/0001): „New nucleic acid expressed at high level in prostatic tumour tissue and encoded polypeptides, useful for treating cancer and screening for therapeutic agents”

auf die oben genannte Person und willigen in die Umschreibung(en) in den amtlichen Registern ein.

We, metaGen Pharmaceuticals GmbH, Oudenarder Strasse 16, D-13347 Berlin, herewith assign the patent application(s) to the above-mentioned inventor and agree with the recordation(s) of the change of applicant in the official registers.

Mit freundlichen Grüßen,
with best regards,

metaGen Pharmaceuticals GmbH i.L.

Mr. Timothy Haines

23-02-04

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de

Ich, Prof. André Rosenthal, nehme hiermit die vorstehende(n) Übertragung(en) an und beantrage die Umschreibung(en) in den amtlichen Registern.

I, Prof. André Rosenthal, herewith accept the above assignment(s) and apply for recordation(s) of the change in the official registers.

Berlin, 25.2.2004

Ort, Datum

André Rosenthal

Prof. André Rosenthal



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin

Einwurf-Einschreiben/registered mail

Dr. Bernd Hinzmann

Saupéweg 10

13 127 Berlin

Dr. Lyn Leaper, Astex
VP, Intellectual Property

phone: ++44(0)1223 226 200

fax: ++44(0)1223 226 201

Dr. Uta Schwidetzky
Patents Manager

phone: ++49(0)30 45082 265

fax: ++49(0)30 45082 101

Berlin, February 23rd, 2004

Re: assignment of metagen patent applications

Sehr geehrter Dr. Hinzmann,

Dear Dr. Hinzmann,

Wir, metaGen Pharmaceuticals GmbH, Oudenarder Strasse 16, D-13347 Berlin,
übertragen hiermit die Patentanmeldung(en)

1. DE198 18 620 A1 (MET/DE/9813), EP1071776 (MET/EP/0035), US divisional MET/US/0325 of US09/673,840 (MET/US/0036), JP2002531052T (MET/JP/0034), "New polypeptides and their nucleic acids, useful for treatment of bladder tumour and identification of therapeutic agents"
2. DE198 18 619.3 (MET/DE/9814), EP1073742 (MET/EP/0038), US divisional MET/US/0323 of US09/673,841 (MET/US/0039), JP2002512023T (MET/JP/0037), "New nucleic acid sequences expressed in bladder tumour tissue, and derived polypeptides, for treatment of bladder tumour and identification of therapeutic agents"
3. DE198 13 835.0 (MET/DE/9805), EP1070125 (MET/EP/0011), US09/646,569 (MET/US/0012), JP2002506639T (MET/JP/0010): "Human nucleic acid sequences and protein products from normal breast tissue, useful for breast cancer therapy"
4. DE 198 13 839.3 (MET/DE/9804), EP 106 43 79 (MET/EP/0008), divisional EP 02090142.7 (MET/EP/0212), US 09/646,673 (MET/US/0009), divisional US 10/131,410 (MET/US/0214), JP2002506643T (MET/JP/0007): "Human nucleic acid sequences and protein products from tumour breast tissue, useful for breast cancer therapy"
- 5. DE198 17 948 A1 (MET/DE/9812), EP1071775 (MET/EP/0032), granted US patent 6,620,923 B1; US divisional US10/407,825 (MET/US/0310), JP2002532055T (MET/JP0031), "New nucleic acid sequences expressed in

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin

uterine cancer tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents"

6. DE198 17 946 A1 (MET/DE/9810), EP1071777 (MET/EP/0026), US09/647,788 (MET/US/0027), US divisional US10/387,348 (MET/US/0230), JP2002512017T (MET/JP/0025), "New nucleic acid sequences expressed in normal uterine tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents"
7. DE198 17 947.2 (MET/DE/9811), EP1080188 (MET/EP/0029), US09/673,400 (MET/US/0030), JP2002512024T (MET/JP/0028), "New nucleic acid sequences expressed in uterine myoma, and derived polypeptides, for treatment of uterine carcinoma and identification of therapeutic agents"
8. DE 198 16 395 A1 (MET/DE/9806), EP1068231 (MET/EP/0014), divisional from US09/646,777 (MET/US/0318), JP2002510486T (MET/JP/0013): "Human nucleic acid sequences from ovarian normal tissue"
9. DE198 17 557 A1 (MET/DE/9807), EP999 45687.4 (MET/EP/0017), divisional EP020 90198.9 (MET/EP/0215); US09/646,778 (MET/US/0018), divisional US10/272,138 (MET/US/0216), JP2002511252T (MET/JP/0016), "Human nucleic acid sequences from ovarian tumour tissue"
10. DE198 18 598 A1 (MET/DE/9808), EP1082420 (MET/EP/0020), divisional US10/330,551 (MET/US/0313), JP2002512022T (MET/JP/0019), "New nucleic acid sequences expressed in normal pancreatic tissues, and derived polypeptides, for treatment of pancreatic cancer and identification of therapeutic agents"
11. DE198 20 190 A1 (MET/DE/9809), EP1076700 (MET/EP/0023), US09/674,266 (MET/US/0024), JP2002512795T (MET/JP/0022), "Human nucleic acid sequences from pancreas tumour tissue"
12. DE 198 11 194.0 (MET/DE/9803), EP1068318 (MET/EP/0005), divisional from US10/391,484 (MET/US/0229), JP2002505878T (MET/JP/0004): "New nucleic acid expressed at high level in normal prostatic tissue and encoded polypeptides, used to treat cancer and screen for therapeutic agents"
13. DE 198 11 193.2 (MET/DE/9802), EP 999177 85.0 (MET/EP/0002), divisional EP 02090141.9 (MET/EP/0211), US09/623,791 (MET/US/0003), divisional from US 09/623,791 (MET/US/0213), JP2002505877T (MET/JP/0001): "New nucleic acid expressed at high level in prostatic tumour tissue and encoded polypeptides, useful for treating cancer and screening for therapeutic agents"
14. EP 03090080.7 (MET/EP/0304), US10/405,975 (MET/US/0305), "Use of TFF3 binding compounds for detecting and treating cancer"
15. DE102 23 246.6 (MET/DE/0113), EP 03090148.2 (MET/EP/0319), US 10/442,658 (MET/US/0320), "Slit1 and MEGF4 isoforms and use thereof"
16. DE102 30 631.1 (MET/DE/0204), PCT/DE 03/01986 (MET/PCT/0322), "Use of a NGAL binding substance for detecting and treating cancer"
17. DE102 25 180.0 (MET/DE/0206), PCT/DE/ 03/01824 (MET/EP/0315), "Protein or peptide and coding nucleic acid and use thereof"

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin

18. DE 102 58 051.0 and PCT/DE/03/04116 (MET/PCT/0334) „Verwendung von an HAT bindenden Substanzen zur Diagnose und Behandlung des Plattenepithelkarzinoms der Lunge“
19. DE 103 15 834.0 (MET/DE/0306), “Human nucleic acid sequences expressed in pancreatic carcinomas”
20. DE 103 16 701.3 (MET/DE/0307), “Human nucleic acid sequences from lung tumours”
21. DE103 45 011.4 (MET/DE/0331), „Use of metaRING binding substances for diagnosing and treatment of cancer”
22. DE103 45 009.2 (MET/DE/0332), „Use of flamingo agonists and/or antagonists for diagnosing and treatment of cancer”
23. DE 103 45 010.6 (MET/DE/0333) „Use of NIFIE14 agonists and/or antagonists for diagnosing and treatment of cancer”
24. DE 103 49 505.3 (MET/DE/0327), „Verwendung von Nukleinsäuren und Peptiden bzw. Proteinen zur Diagnose und Behandlung von Kolonkarzinomen“
25. DE 103 39 820.1 (MET/DE/0329), „Use of GPR49 binding substances for diagnosing and treatment of cancer”
26. DE102 34 901.0 (MET/DE/0202), PCT/DE03/02159 (MET/PCT/0324), „Use of MRP4 binding compounds for detecting and treating cancer”
27. DE 103 00 861.6 (MET/DE/0232) and PCT/DE04/000029 (MET/PCT/0336) „Verwendung von an FABP4 bindenden Substanzen zur Diagnose und Behandlung des Harnblasenkarzinoms“
28. DE 103 01 592.2 (MET/DE/0233) PCT/DE04/000092 (MET/PCT/0337) „Verwendung von an GSTM4 bindenden Substanzen zur Diagnose und Behandlung des Harnblasenkarzinoms“
29. DE103 09 729.5 (MET/DE/0231) “Human nucleic acids expressed in bladder tumours”
30. DE103 09 985.9 (MET/DE/0302) “Human nucleic acid sequences expressed in prostate carcinomas” (appn I)
31. DE 103 22 134.4 (MET/DE/0321) “Human nucleic acid sequences expressed in prostate carcinomas” (appn II)

auf die oben genannte Person und willigen in die Umschreibung(en) in den amtlichen Registern ein.

We, metaGen Pharmaceuticals GmbH, Oudenarder Strasse 16, D-13347 Berlin, herewith assign the patent application(s) to the above-mentioned inventor and agree with the recordation(s) of the change of applicant in the official registers.

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de



Oudenarder Straße 16
D-13347 Berlin

Mit freundlichen Grüßen,
with best regards,

metaGen Pharmaceuticals GmbH i.L.

A handwritten signature in black ink, appearing to read "Timothy Haines", written over a horizontal line.

Mr. Timothy Haines

23.02.04.

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de

Ich, Dr. Bernd Hinzmann, nehme hiermit die vorstehende(n) Übertragung(en) an und beantrage die Umschreibung(en) in den amtlichen Registern.

I, Dr. Bernd Hinzmann, herewith accept the above assignment(s) and apply for recordation(s) of the change in the official registers.

Berlin, den 23. 2004
Ort, Datum


Dr. Bernd Hinzmann



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 BerlinEinwurf-Einschreiben/registered mailDr. Thomas Specht
Trainsjochstr. 19

83088 Kiefersfelden

Dr. Lyn Leaper, Astex
VP, Intellectual Property

phone: ++44(0)1223 226 200

fax: ++44(0)1223 226 201

Dr. Uta Schwidetzky
Patents Manager

phone: ++49(0)30 45082 265

fax: ++49(0)30 45082 101

Berlin, February 23rd, 2004**Re: assignment of metagen patent applications**Sehr geehrter Dr. Specht,
Dear Dr. Specht,Wir, metaGen Pharmaceuticals GmbH, Oudenarder Strasse 16, D-13347 Berlin,
übertragen hiermit die Patentanmeldung(en)

1. DE198 18 620 A1 (MET/DE/9813), EP1071776 (MET/EP/0035), US divisional MET/US/0325 of US09/673,840 (MET/US/0036), JP2002531052T (MET/JP/0034), "New polypeptides and their nucleic acids, useful for treatment of bladder tumour and identification of therapeutic agents"
2. DE198 18 619.3 (MET/DE/9814), EP1073742 (MET/EP/0038), US divisional MET/US/0323 of US09/673,841 (MET/US/0039), JP2002512023T (MET/JP/0037), "New nucleic acid sequences expressed in bladder tumour tissue, and derived polypeptides, for treatment of bladder tumour and identification of therapeutic agents"
3. DE198 13 835.0 (MET/DE/9805), EP1070125 (MET/EP/0011), US09/646,569 (MET/US/0012), JP2002506639T (MET/JP/0010): "Human nucleic acid sequences and protein products from normal breast tissue, useful for breast cancer therapy"
4. DE 198 13 839.3 (MET/DE/9804), EP 106 43 79 (MET/EP/0008), divisional EP 02090142.7 (MET/EP/0212), US 09/646,673 (MET/US/0009), divisional US 10/131,410 (MET/US/0214), JP2002506643T (MET/JP/0007): "Human nucleic acid sequences and protein products from tumour breast tissue, useful for breast cancer therapy"
5. DE198 17 948 A1 (MET/DE/9812), EP1071775 (MET/EP/0032), granted US patent 6,620,923 B1; US divisional US10/407,825 (MET/US/0310), JP2002532055T (MET/JP0031), "New nucleic acid sequences expressed in uterine cancer tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents"

Handelsregister
AG Berlin-Charlottenburg
HRB 61730Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00Ust.Nr.
DE 185525651

www.metaGen.de



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin

6. DE198 17 946 A1 (MET/DE/9810), EP1071777 (MET/EP/0026), US09/647,788 (MET/US/0027), US divisional US10/387,348 (MET/US/0230), JP2002512017T (MET/JP/0025), "New nucleic acid sequences expressed in normal uterine tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents"
7. DE198 17 947.2 (MET/DE/9811), EP1080188 (MET/EP/0029), US09/673,400 (MET/US/0030), JP2002512024T (MET/JP/0028), "New nucleic acid sequences expressed in uterine myoma, and derived polypeptides, for treatment of uterine carcinoma and identification of therapeutic agents"
8. DE 198 16 395 A1 (MET/DE/9806), EP1068231 (MET/EP/0014), divisional from US09/646,777 (MET/US/0318), JP2002510486T (MET/JP/0013): "Human nucleic acid sequences from ovarian normal tissue"
9. DE198 17 557 A1 (MET/DE/9807), EP999 45687.4 (MET/EP/0017), divisional EP020 90198.9 (MET/EP/0215); US09/646,778 (MET/US/0018), divisional US10/272,138 (MET/US/0216), JP2002511252T (MET/JP/0016), "Human nucleic acid sequences from ovarian tumour tissue"
10. DE198 18 598 A1 (MET/DE/9808), EP1082420 (MET/EP/0020), divisional US10/330,551 (MET/US/0313), JP2002512022T (MET/JP/0019), "New nucleic acid sequences expressed in normal pancreatic tissues, and derived polypeptides, for treatment of pancreatic cancer and identification of therapeutic agents"
11. DE198 20 190 A1 (MET/DE/9809), EP1076700 (MET/EP/0023), US09/674,266 (MET/US/0024), JP2002512795T (MET/JP/0022), "Human nucleic acid sequences from pancreas tumour tissue"
12. DE 198 11 194.0 (MET/DE/9803), EP1068318 (MET/EP/0005), divisional from US10/391,484 (MET/US/0229), JP2002505878T (MET/JP/0004): "New nucleic acid expressed at high level in normal prostatic tissue and encoded polypeptides, used to treat cancer and screen for therapeutic agents"
13. DE 198 11 193.2 (MET/DE/9802), EP 999177 85.0 (MET/EP/0002), divisional EP 02090141.9 (MET/EP/0211), US09/623,791 (MET/US/0003), divisional from US 09/623,791 (MET/US/0213), JP2002505877T (MET/JP/0001): "New nucleic acid expressed at high level in prostatic tumour tissue and encoded polypeptides, useful for treating cancer and screening for therapeutic agents"
14. DE102 25 180.0 (MET/DE/0206), PCT/DE/ 03/01824 (MET/EP/0315), "Protein or peptide and coding nucleic acid and use thereof"
15. DE 103 15 834.0 (MET/DE/0306), "Human nucleic acid sequences expressed in pancreatic carcinomas"

auf die oben genannte Person und willigen in die Umschreibung(en) in den amtlichen Registern ein.

We, metaGen Pharmaceuticals GmbH, Oudenarder Strasse 16, D-13347 Berlin,

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de




Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin

herewith assign the patent application(s) to the above-mentioned inventor and agree with the recordation(s) of the change of applicant in the official registers.


Mit freundlichen Grüßen,
with best regards,

metaGen Pharmaceuticals GmbH i.L.



Mr. Timothy Haines

23-02-04



27/2/04

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de

PATENT
REEL: 015083 FRAME: 0349

Ich, Dr. Thomas Specht, nehme hiermit die vorstehende(n) Übertragung(en) an und beantrage die Umschreibung(en) in den amtlichen Registern.

I, Dr. Thomas Specht, herewith accept the above assignment(s) and apply for recordation(s) of the change in the official registers.

Klostersfelden 27/2/04
Ort, Datum

Thomas Specht
Dr. Thomas Specht



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin

Einwurf-Einschreiben/registered mail

Dr. Christian Pilarsky
Wallotstrasse 35

01 309 Dresden

Dr. Lyn Leaper, Astex
VP, Intellectual Property

phone: ++44(0)1223 226 200
fax: ++44(0)1223 226 201

Dr. Uta Schwidetzky
Patents Manager

phone: ++49(0)30 45082 265
fax: ++49(0)30 45082 101

Berlin, February 23rd, 2004**Re: assignment of metagen patent applications**

Sehr geehrter Dr. Pilarsky,
Dear Dr. Pilarsky,

Wir, metaGen Pharmaceuticals GmbH, Oudenarder Strasse 16, D-13347 Berlin,
übertragen hiermit die Patentanmeldung(en)

1. DE198 18 620 A1 (MET/DE/9813), EP1071776 (MET/EP/0035), US divisional MET/US/0325 of US09/673,840 (MET/US/0036), JP2002531052T (MET/JP/0034), "New polypeptides and their nucleic acids, useful for treatment of bladder tumour and identification of therapeutic agents"
2. DE198 18 619.3 (MET/DE/9814), EP1073742 (MET/EP/0038), US divisional MET/US/0323 of US09/673,841 (MET/US/0039), JP2002512023T (MET/JP/0037), "New nucleic acid sequences expressed in bladder tumour tissue, and derived polypeptides, for treatment of bladder tumour and identification of therapeutic agents"
3. DE198 13 835.0 (MET/DE/9805), EP1070125 (MET/EP/0011), US09/646,569 (MET/US/0012), JP2002506639T (MET/JP/0010): "Human nucleic acid sequences and protein products from normal breast tissue, useful for breast cancer therapy"
4. DE 198 13 839.3 (MET/DE/9804), EP 106 43 79 (MET/EP/0008), divisional EP 02090142.7 (MET/EP/0212), US 09/646,673 (MET/US/0009), divisional US 10/131,410 (MET/US/0214), JP2002506643T (MET/JP/0007): "Human nucleic acid sequences and protein products from tumour breast tissue, useful for breast cancer therapy"
- 5. DE198 17 948 A1 (MET/DE/9812), EP1071775 (MET/EP/0032), granted US patent 6,620,923 B1; US divisional US10/407,825 (MET/US/0310), JP2002532055T (MET/JP0031), "New nucleic acid sequences expressed in

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de

PATENT
REEL: 015083 FRAME: 0351



Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin

uterine cancer tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents"

6. DE198 17 946 A1 (MET/DE/9810), EP1071777 (MET/EP/0026), US09/647,788 (MET/US/0027), US divisional US10/387,348 (MET/US/0230), JP2002512017T (MET/JP/0025), "New nucleic acid sequences expressed in normal uterine tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents"
7. DE198 17 947.2 (MET/DE/9811), EP1080188 (MET/EP/0029), US09/673,400 (MET/US/0030), JP2002512024T (MET/JP/0028), "New nucleic acid sequences expressed in uterine myoma, and derived polypeptides, for treatment of uterine carcinoma and identification of therapeutic agents"
8. DE 198 16 395 A1 (MET/DE/9806), EP1068231 (MET/EP/0014), divisional from US09/646,777 (MET/US/0318), JP2002510486T (MET/JP/0013): "Human nucleic acid sequences from ovarian normal tissue"
9. DE198 17 557 A1 (MET/DE/9807), EP999 45687.4 (MET/EP/0017), divisional EP020 90198.9 (MET/EP/0215); US09/646,778 (MET/US/0018), divisional US10/272,138 (MET/US/0216), JP2002511252T (MET/JP/0016), "Human nucleic acid sequences from ovarian tumour tissue"
10. DE198 18 598 A1 (MET/DE/9808), EP1082420 (MET/EP/0020), divisional US10/330,551 (MET/US/0313), JP2002512022T (MET/JP/0019), "New nucleic acid sequences expressed in normal pancreatic tissues, and derived polypeptides, for treatment of pancreatic cancer and identification of therapeutic agents"
11. DE198 20 190 A1 (MET/DE/9809), EP1076700 (MET/EP/0023), US09/674,266 (MET/US/0024), JP2002512795T (MET/JP/0022), "Human nucleic acid sequences from pancreas tumour tissue"
12. DE 198 11 194.0 (MET/DE/9803), EP1068318 (MET/EP/0005), divisional from US10/391,484 (MET/US/0229), JP2002505878T (MET/JP/0004): "New nucleic acid expressed at high level in normal prostatic tissue and encoded polypeptides, used to treat cancer and screen for therapeutic agents"
13. DE 198 11 193.2 (MET/DE/9802), EP 999177 85.0 (MET/EP/0002), divisional EP 02090141.9 (MET/EP/0211), US09/623,791 (MET/US/0003), divisional from US 09/623,791 (MET/US/0213), JP2002505877T (MET/JP/0001): "New nucleic acid expressed at high level in prostatic tumour tissue and encoded polypeptides, useful for treating cancer and screening for therapeutic agents"
14. DE102 23 246.6 (MET/DE/0113), EP 03090148.2 (MET/EP/0319), US 10/442,658 (MET/US/0320), "Slit1 and MEGF4 isoforms and use thereof"
15. DE102 25 180.0 (MET/DE/0206), PCT/DE/ 03/01824 (MET/EP/0315), "Protein or peptide and coding nucleic acid and use thereof"
16. DE 103 15 834.0 (MET/DE/0306), "Human nucleic acid sequences expressed in pancreatic carcinomas"

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de

metaGen

Pharmaceuticals GmbH

Oudenarder Straße 16
D-13347 Berlin


17. DE102 34 901.0 (MET/DE/0202), PCT/DE03/02159 (MET/PCT/0324),
„Use of MRP4 binding compounds for detecting and treating cancer”
18. DE103 09 985.9 (MET/DE/0302) “Human nucleic acid sequences expressed
in prostate carcinomas” (appn I)
19. DE 103 22 134.4 (MET/DE/0321) “Human nucleic acid sequences
expressed in prostate carcinomas” (appn II)

auf die oben genannte Person und willigen in die Umschreibung(en) in den
amtlichen Registern ein.

We, metaGen Pharmaceuticals GmbH, Oudenarder Strasse 16, D-13347 Berlin,
herewith assign the patent application(s) to the above-mentioned inventor and agree
with the recordation(s) of the change of applicant in the official registers.

Mit freundlichen Grüßen,
with best regards,

metaGen Pharmaceuticals GmbH i.L.



Mr. Timothy Haines

23-2-04

Handelsregister
AG Berlin-Charlottenburg
HRB 61730

Bankverbindung
Commerzbank AG, Berlin
Konto-Nr. 102 700 200
BLZ 100 400 00

Ust.Nr.
DE 185525651

www.metaGen.de

Ich, Dr. Christian Pilarsky, nehme hiermit die vorstehende(n) Übertragung(en) an und beantrage die Umschreibung(en) in den amtlichen Registern.

I, Dr. Christian Pilarsky, herewith accept the above assignment(s) and apply for recordation(s) of the change in the official registers.

Dresden 2.3.04
Ort, Datum


Dr. Christian Pilarsky